Novartis completes acquisition of Regulus Therapeutics

Novartis (NVS) announced that it has successfully completed its acquisition of Regulus Therapeutics (RGLS). With the completion of the acquisition, shares of common stock of Regulus have ceased trading on the Nasdaq Stock Market and Regulus is now an indirect wholly owned subsidiary of Novartis. As a result of the merger, each share issued and outstanding and not tendered in the tender offer was canceled and extinguished and automatically converted into the right to receive the same consideration, including the CVR, per share payable in the tender offer. “We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-class medicine that can help treat patients suffering from ADPKD – autosomal dominant polycystic kidney disease – the most common genetic cause of renal failure worldwide. We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need,” said Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis.